Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 22 days ago
Share
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
15500 patients around the world
Available in
United States, Chile
Janssen Research & Development, LLC
15500
Patients around the world
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
See details
Contact us
Contact us
Study
LIBREXIA-AF
Sponsor
Janssen Research & Development, LLC
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05757869
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent